University of Pittsburgh researchers have confirmed a new blood test platform that can measure over a hundred biomarkers of Alzheimer’s disease simultaneously. This platform can help capture the complex nature of Alzheimer’s pathology and improve early disease detection. By detecting changes associated with Alzheimer’s disease, such as neuroinflammation and brain dysfunction, clinicians can enhance the effectiveness of treatment. The platform, called NULISAseq CNS Disease 120 Panel, was tested on blood samples from cognitively normal older adults in Pennsylvania and validated against traditional Alzheimer’s biomarkers. Researchers hope to use this platform to track biomarker changes over time and develop guidelines for early intervention and treatment planning.
Source link
Scientists validate new lab test platform for blood biomarkers of Alzheimer’s disease
